Danaher Diagnostics LLC and Danaher Ventures LLC, two subsidiaries of Danaher Corporation (NYSE: DHR) ("Danaher"), a global science and technology innovator, announced today that they have formed an investment partnership with Innovaccer Inc., a leading healthcare artificial intelligence (AI) company.

Shanghai announced on Wednesday to encourage wholly foreign-invested hospitals to be established in the municipality's key economic zones, areas where the biopharmaceutical industry clusters, and downtown districts with a high concentration of expat residents.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

The Bill & Melinda Gates Foundation awarded more than 500 new grants in the fourth quarter of 2024, many of which are related to diagnostic and omics projects. The following is a selection of notable grants:

Italian VC XGEN Venture has closed a 180 million euro ($190 million) fund for biotech and medtech companies.

Personalis, Inc. (NASDAQ: PSNL) announced today agreements with long time collaborators Merck and Moderna that accelerate the advancement of the company’s business strategy. The company has received an investment from Merck, known as MSD outside the United States and Canada, and separately has signed a multi-year extension with Moderna to utilize Personalis’ ImmunoID NeXT Platform® and technology for V940/mRNA-4157, an investigational individualized neoantigen therapy (INT), being jointly developed by Merck and Moderna.

North China's Tianjin Municipality issued a license for medical services on Monday to a wholly foreign-owned, third-grade general hospital, the first of its kind in the country.

Suraksha Diagnostic Ltd, an integrated diagnostic chain based in Kolkata, has successfully raised ₹254 crore from anchor investors ahead of its initial public offering (IPO). This significant funding comes just a day before the company opens its IPO for public subscription. The IPO is set to attract considerable attention, given the robust backing from prominent mutual funds and the company’s extensive operational network.

Chinese authorities recently released revised rules on foreign investors' strategic investment in listed companies in a move to encourage foreign investors to make long-term and value investments in the country.

Auckland-based biotechnology company DNAiTECH has secured NZD $1 million in funding to advance its development of instant diagnostic tests that do not require a laboratory.